Simplified perioperative serplulimab and chemotherapy for resectable squamous NSCLC: a phase II trial with biomarker analysis [0.03%]
用于可切除型肺鳞癌的新辅助斯鲁利单抗联合化疗简化方案的II期临床研究及生物标志物分析
Fangqiu Fu,Haoxuan Wu,Chaoqiang Deng et al.
Fangqiu Fu et al.
Purpose: Squamous non-small cell lung cancer (sq-NSCLC) is a distinct subtype of NSCLC. This exploratory, phase II study investigated the feasibility and efficacy of a four-cycle perioperative regimen combining serplulima...
Phase 2 study of talabostat, a small molecule inhibitor of dipeptidyl peptidases (DPP), administered in combination with pembrolizumab in patients with small cell neuroendocrine prostate cancer [0.03%]
泰拉布司联合派姆单抗治疗小细胞神经内分泌前列腺癌二期临床研究
Rahul Aggarwal,Jingsong Zhang,Paul Monk et al.
Rahul Aggarwal et al.
Background: Small cell neuroendocrine prostate cancer (SCNC) is a lethal subset of prostate cancer with limited treatment options. Talabostat, an oral small molecule inhibitor of dipeptidyl peptidases (DPP4 and DPP 8/9) t...
Michelle L McKeague,Sokratis A Apostolidis
Michelle L McKeague
Checkpoint blockade immunotherapy has changed the landscape of cancer treatment for many types of malignancies, but it still does not work for all individuals and for all tumor types. Much work over the past decade has been dedicated to dis...
Sensory neuron-derived CCL5 orchestrates an immunosuppressive niche via regulatory T cells to fuel head and neck tumor progression [0.03%]
感觉神经源性CCL5通过调节性T细胞协调免疫抑制微环境以促进头颈部肿瘤进展
Kailiu Wu,Zhen Zhang,Xing Qin et al.
Kailiu Wu et al.
Background: Perineural invasion (PNI) is a hallmark of malignancy in solid tumors, including oral squamous cell carcinoma (OSCC), and is closely associated with poor prognosis. Emerging evidence suggests a critical associ...
VISTA neutralization by immunization reprograms immunosuppression and augments vaccine efficacy in renal carcinoma [0.03%]
通过免疫接种中和VISTA可重新编程免疫抑制并增强肾癌疫苗效力
Jiawei Wang,Zhenzhen Wang,Wanting Zhao et al.
Jiawei Wang et al.
Background: Renal carcinoma remains a highly lethal malignancy, and tumor vaccine efficacy is frequently hampered by a profoundly immunosuppressive tumor microenvironment. V-domain Ig suppressor of T-cell activation (VIST...
Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies [0.03%]
NKG2A靶向抗体S095029单药和联合抗PD-1治疗晚期恶性肿瘤的Ⅰ期多中心研究
Aung Naing,Anna Spreafico,Minal Barve et al.
Aung Naing et al.
Background: NKG2A is a C-type lectin that heterodimerizes with CD94 creating an inhibitory immunoreceptor. S095029 is a fully human monoclonal IgG1 anti-NKG2A antibody with attenuated Fc-effector functions that specifical...
LGALS9 blockade augments vaccine-induced immune responses against prostate cancer [0.03%]
LGALS9阻断可增强前列腺癌疫苗诱导的免疫反应
Bowen Lu,Ning Liu,Wanting Zhao et al.
Bowen Lu et al.
Background: Prostate-specific membrane antigen (PSMA)-based vaccination represents a promising immunotherapeutic strategy for prostate cancer; however, its efficacy remains constrained by tumor-induced immune evasion and ...
PSCA CAR Vδ1 T cells: a safer off-the-shelf CAR T therapy for pancreatic cancer? [0.03%]
针对胰腺癌的PSCA CAR Vδ1 T细胞：一种更安全的现货型CAR T疗法？
Joseph A Fraietta,Jason J Lohmueller
Joseph A Fraietta
Pancreatic cancer remains among the deadliest malignancies, with a 5-year survival of ~13%. Chimeric antigen receptor (CAR) T -cell therapy offers hope, but conventional αβ T cells can trigger severe toxicities, including graft-versus-hos...
Endogenous neoantigen-specific antibodies mediate antitumor responses and determine vaccine efficacy [0.03%]
内源性neoantigen特异性抗体介导抗肿瘤反应并决定疫苗的疗效
Sirajbir S Sodhi,John S Wang,David T Severson et al.
Sirajbir S Sodhi et al.
Background: The contribution of B cells to antitumor immunity remains controversial, with studies reporting varied effects across cancer types. Even less is known about the role of the endogenous humoral response, includi...
Correlation between recognition of autologous tumor organoids by tumor-infiltrating lymphocytes from metastatic epithelial cancers and clinical response [0.03%]
肿瘤浸润淋巴细胞识别转移性上皮癌自体类器官与临床反应之间的相关性研究
Alexandra M Gustafson,Aarushi Bhasin,Billel Gasmi et al.
Alexandra M Gustafson et al.
Background: Neoantigen-specific tumor-infiltrating lymphocytes (TILs) have the ability to mediate responses in patients with metastatic epithelial cancers. While some identified factors are associated with response, there...